Molecular Mechanisms of Myeloid Cell Differentiation and Resistance to Anti-tumor Immunity
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 31
Special Issue Editor
Interests: immunotherapy, myeloid targeting, cell and gene therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapies have revolutionized the treatment of solid tumors over the past decade. However, during tumor progression, tumors implement profound immunosuppression within the tumor microenvironment (TME), leading to resistance to immunotherapies and recurring tumor disease.
Chronic cancer inflammation over-activates the immune system, leading to a dramatic expansion and the recruitment of myeloid progenitors that fail to mature into functional myeloid effector cells, thus leading to an imbalance of inflammation and anti-inflammation. This unresolved pathologic inflammation creates profound alterations in the intrinsic molecular, epigenetic, and metabolic networks of the myeloid progenitor pool, which is amplified by the TME, by competition for essential nutrients, and by hypoxia-induced metabolic rewiring at the tumor site. Therefore, persistent myelopoiesis and aberrant myeloid differentiation contribute to cancer progression.
The editorial aims to (1) define the molecular, epigenetic, and metabolic networks implicated in persistent myelopoiesis observed in cancer patients, (2) discuss the impact of dysfunctional myeloid differentiation on clinical outcomes, and (3) explore new biomarkers and therapeutic targets in order to restore the differentiation of myeloid progenitors and myeloid cells towards an effector phenotype, thus increasing host antitumor immunity.
Restoring the profound alterations in myelopoiesis may help to overcome resistance to immunotherapy in patients with cold tumors, where myeloid cells are key players in mediating immune evasion.
Dr. Laura Strauss
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- emergency myelopoiesis
- MDSC
- immunotherapy resistance
- dysfunctional myeloid differentiation
- TME in cold tumors
